ELVN Sale Disclosure
Collins Helen Louise · SEC Form 4 · Filed Oct 21, 2026
Sale
Calculated transaction value
$192.34K
Collins Helen Louise Chief Medical Officer
ELVN
Enliven Therapeutics
ELVN
Transaction date
Oct 19, 2026
Public filing date
Oct 21, 2026
Filing lag
Filed 2 days later
ELVN daily price context
Close on/before transaction
$38.7
Oct 19, 2026
First close after public filing
$41.93
Oct 22, 2026
Return after filing · so far
+19.82%
Through Nov 10, 2026
Source details
- Reported owner
- Not disclosed
- Source asset code
- Security
- Security
- Common Stock
- Quantity / price
- 5,000 shares @ $38.47
- SEC ownership
- Direct
- Transaction code
- S
- Form
- 4
- Filing identifier
- 0001701247-26-000014
Filing cohort
Transactions in this filing
Showing 3 of 3
Trades
3
Issuers
1
Estimated value
$204.74K
Buys / sales
0 / 1
| Issuer | Transaction | Traded | Value |
|---|---|---|---|
| Enliven Therapeutics, Inc. ELVN | Exercise | Oct 19, 2026 | $12.4K |
| Enliven Therapeutics, Inc. ELVN | Exercise | Oct 19, 2026 | $0 |
| Enliven Therapeutics, Inc. ELVN Current | Sale | Oct 19, 2026 | $192.34K |